Kólistímetat Natríum Xellia

Colistimethate Sodium, the active ingredient in Kólistímetat Natríum, is a polymyxin antibiotic presented as a sterile injectable solution for intravenous and intrathecal use. It treats serious infections caused by susceptible Gram‑negative bacteria, including Pseudomonas aeruginosa, in hospitalized patients.

GNH USA supplies Kólistímetat Natríum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Colistimethate Sodium is used to treat infections caused by Gram‑negative bacteria in critical care settings.

- Ventilator‑associated pneumonia: helps eradicate Pseudomonas and other resistant Gram‑negative pathogens in mechanically ventilated patients. - Complicated urinary tract infections: provides bactericidal activity against susceptible Gram‑negative organisms in the urinary tract. - Intra‑abdominal infections: targets Gram‑negative bacteria involved in peritonitis and postoperative abdominal infections. - Serious Gram‑negative infections: treats life‑threatening infections caused by susceptible organisms when other antibiotics are ineffective.

Colistimethate Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nephrotoxicity: rise in serum creatinine and reduced renal clearance. - Neurotoxicity: tingling, dizziness, or paresthesia. - Nausea and vomiting: gastrointestinal upset. - Fever or chills: infusion‑related reactions.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions. - Severe neuromuscular blockade: respiratory muscle weakness or paralysis. - Ototoxicity: hearing loss or tinnitus.

When using colistimethate sodium, clinicians should observe several safety measures to minimize risk.

- Renal monitoring: check serum creatinine and urine output regularly. - Neuromuscular assessment: observe for muscle weakness or respiratory depression. - Dose adjustment: modify dosage in patients with impaired renal function. - Avoid concomitant nephrotoxic drugs: limit use with aminoglycosides, vancomycin, or amphotericin B. - Pregnancy and lactation: use only if benefits outweigh potential unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Colistimethate sodium can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides (e.g., gentamicin): additive nephrotoxicity. - Vancomycin: increased risk of kidney injury. - Neuromuscular blocking agents (e.g., pancuronium): enhanced neuromuscular blockade. - Amphotericin B: synergistic renal toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may worsen renal function. - Loop diuretics (e.g., furosemide): can potentiate nephrotoxic effects. - Other polymyxins or colistin formulations: risk of cumulative toxicity.